{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:06:30Z","timestamp":1781913990520,"version":"3.54.5"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Immunology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.humimm.2024.110810","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T19:43:19Z","timestamp":1716493399000},"page":"110810","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Biologicals in the prevention and treatment of intestinal graft rejection: The state of the art Biologicals in Intestinal Transplantation"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8519-6812","authenticated-orcid":false,"given":"Naomi","family":"Karmi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werna T.C.","family":"Uniken Venema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frans","family":"van der Heide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora A.M.","family":"Festen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Dijkstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humimm.2024.110810_b0005","unstructured":"R. Venick, International Intestinal Transplant Registry: 2023 Update, (2023)."},{"key":"10.1016\/j.humimm.2024.110810_b0010","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.3390\/ijms24054541","article-title":"Intestinal transplant immunology and intestinal graft rejection: from basic mechanisms to potential biomarkers","volume":"24","author":"Rumbo","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.humimm.2024.110810_b0015","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1056\/NEJMra033540","article-title":"Immunosuppressive drugs for kidney transplantation","volume":"351","author":"Halloran","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.humimm.2024.110810_b0020","doi-asserted-by":"crossref","unstructured":"S.S. Guimaraes Koch, R. Thorpe, N. Kawasaki, M.-P. Lefranc, S. Malan, A.C.R. Martin, G. Mignot, A. Pl\u00fcckthun, M. Rizzi, S. Shubat, K. Weisser, R. Balocco, International nonproprietary names for monoclonal antibodies: an evolving nomenclature system, mAbs 14 (2022) 2075078. DOI: 10.1080\/19420862.2022.2075078.","DOI":"10.1080\/19420862.2022.2075078"},{"key":"10.1016\/j.humimm.2024.110810_b0025","doi-asserted-by":"crossref","first-page":"e0208922","DOI":"10.1371\/journal.pone.0208922","article-title":"Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-\u03b1 biologicals and an Infliximab-biosimilar","volume":"13","author":"Buurman","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.humimm.2024.110810_b0030","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1097\/TP.0000000000003074","article-title":"Association of more intensive induction with less acute rejection following intestinal transplantation: results of 445 consecutive cases from a single center","volume":"104","author":"Vianna","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.humimm.2024.110810_b0035","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.transproceed.2023.03.006","article-title":"Immunosuppression protocols in intestinal and multivisceral transplantation\u2014a literature review","volume":"55","author":"Ferreira","year":"2023","journal-title":"Transpl. Proc."},{"key":"10.1016\/j.humimm.2024.110810_b0040","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/MOT.0000000000000958","article-title":"Update on immunosuppressive strategies in intestinal transplantation","volume":"27","author":"Merola","year":"2022","journal-title":"Curr. Opin. Organ Transplant."},{"key":"10.1016\/j.humimm.2024.110810_b0045","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000001512","article-title":"The first collective examination of immunosuppressive practices among american intestinal transplant centers","author":"Weiner","year":"2023","journal-title":"Transplant Direct"},{"key":"10.1016\/j.humimm.2024.110810_b0050","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/MOT.0000000000000290","article-title":"The role of biologicals in intestinal transplantation","volume":"21","author":"Pascher","year":"2016","journal-title":"Curr. Opin. Organ Transplant."},{"key":"10.1016\/j.humimm.2024.110810_b0055","doi-asserted-by":"crossref","first-page":"e0130026","DOI":"10.1371\/journal.pone.0130026","article-title":"Impact of pre-transplant anti-T cell globulin (ATG) on immune recovery after myeloablative allogeneic peripheral blood stem cell transplantation","volume":"10","author":"Servais","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.humimm.2024.110810_b0060","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1097\/01.tp.0000235549.47976.d0","article-title":"Rabbit antithymocyte globulin inhibits monocyte-derived dendritic cells maturation in vitro and polarizes monocyte-derived dendritic cells towards tolerogenic dendritic cells expressing indoleamine 2,3-dioxygenase","volume":"82","author":"Gillet-Hladky","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.humimm.2024.110810_b0065","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1567-5769(02)00253-9","article-title":"Effects of anti-lymphocytes and anti-thymocytes globulin on human dendritic cells","volume":"3","author":"Monti","year":"2003","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.humimm.2024.110810_b0070","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.tp.0000295329.29278.8d","article-title":"New insights into the mechanisms of action of thymoglobulin","volume":"84","author":"Brayman","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.humimm.2024.110810_b0075","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1016\/j.transproceed.2012.07.016","article-title":"Intestinal and multivisceral transplantation immunosuppression protocols\u2014literature review","volume":"44","author":"Trevizol","year":"2012","journal-title":"Transpl. Proc."},{"key":"10.1016\/j.humimm.2024.110810_b0080","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/MOT.0000000000000853","article-title":"Donor-specific antibody and sensitized patients in intestinal transplantation","volume":"26","author":"Matsumoto","year":"2021","journal-title":"Curr. Opin. Organ Transplant."},{"key":"10.1016\/j.humimm.2024.110810_b0085","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40272-022-00512-3","article-title":"Immunosuppression regimens for intestinal transplantation in children","volume":"24","author":"Raghu","year":"2022","journal-title":"Pediatr. Drugs"},{"key":"10.1016\/j.humimm.2024.110810_b0090","first-page":"373","article-title":"Basiliximab, mechanism of action and pharmacological properties","volume":"58","author":"Kapic","year":"2004","journal-title":"Med. Arh."},{"key":"10.1016\/j.humimm.2024.110810_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/S1091-255X(01)00073-7","article-title":"Ninety-five cases of intestinal transplantation at the University of Miami","volume":"6","author":"Nishida","year":"2002","journal-title":"Gastrointest. Surg."},{"key":"10.1016\/j.humimm.2024.110810_b0100","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1097\/TP.0b013e3182888df0","article-title":"Impact of positive flow cytometry crossmatch on outcomes of intestinal\/multivisceral transplantation: role anti-IL-2 receptor antibody","volume":"95","author":"Kubal","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.humimm.2024.110810_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.humimm.2024.110787","article-title":"Clinical outcomes of intestinal transplant recipients receiving maintenance basiliximab, sublingual tacrolimus and prednisone: A case series","author":"Di Cocco","year":"2024","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.humimm.2024.110810_b0110","doi-asserted-by":"crossref","first-page":"e12956","DOI":"10.1111\/ctr.12956","article-title":"Severe acute cellular rejection after intestinal transplantation is associated with poor patient and graft survival","volume":"31","author":"Huard","year":"2017","journal-title":"Clin. Transplant."},{"key":"10.1016\/j.humimm.2024.110810_b0115","doi-asserted-by":"crossref","first-page":"e527","DOI":"10.1097\/TXD.0000000000000973","article-title":"Safe and successful treatment of acute cellular rejection of an intestine and abdominal wall transplant with vedolizumab","volume":"6","author":"Trentadue","year":"2020","journal-title":"Transplant. Direct"},{"key":"10.1016\/j.humimm.2024.110810_b0120","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/ecco-jcc\/jjw053","article-title":"Mechanism of action of anti-TNF therapy in inflammatory bowel disease","volume":"10","author":"Levin","year":"2016","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.humimm.2024.110810_b0125","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2022.869399","article-title":"Innovations in immunosuppression for intestinal transplantation","volume":"9","author":"Dogra","year":"2022","journal-title":"Front. Nutr."},{"key":"10.1016\/j.humimm.2024.110810_b0130","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/ajt.16283","article-title":"Rejection of intestinal allotransplants is driven by memory T helper type 17 immunity and responds to infliximab","volume":"21","author":"Kroemer","year":"2021","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.humimm.2024.110810_b0135","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/j.1600-6143.2011.03497.x","article-title":"Tumor necrosis factor alpha inhibitors as immunomodulatory antirejection agents after intestinal transplantation","volume":"11","author":"Gerlach","year":"2011","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.humimm.2024.110810_b0140","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.transproceed.2015.11.033","article-title":"A case report of acute cellular rejection following intestinal transplantation managed with adalimumab","volume":"48","author":"Rao","year":"2016","journal-title":"Transpl. Proc."},{"key":"10.1016\/j.humimm.2024.110810_b0145","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1053\/j.gastro.2015.10.046","article-title":"Leukocyte trafficking to the small intestine and colon","volume":"150","author":"Habtezion","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.humimm.2024.110810_b0150","doi-asserted-by":"crossref","first-page":"e326","DOI":"10.1097\/MD.0000000000000326","article-title":"PRISMA\u2014efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials","volume":"93","author":"Wang","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.humimm.2024.110810_b0155","article-title":"Gut-associated lymphoid tissue attrition associates with response to anti-\u03b14\u03b27 therapy in ulcerative colitis","author":"Canales-Herrerias","year":"2023","journal-title":"Immunology"},{"key":"10.1016\/j.humimm.2024.110810_b0160","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2023-331696","article-title":"Fluorescently labelled vedolizumab to visualise drug distribution and mucosal target cells in inflammatory bowel disease","author":"Gabri\u00ebls","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.humimm.2024.110810_b0165","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1097\/01.tp.0000521364.18534.8f","article-title":"Vedolizumab for the treatment of refractory severe rejection in intestinal transplantation","volume":"101","author":"Beduschi","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.humimm.2024.110810_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.humimm.2024.110767","article-title":"Including the liver in the visceral allograft: Impact on donor-specific anti-HLA antibodies and long-term outcomes","volume":"85","author":"Abele","year":"2024","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.humimm.2024.110810_b0175","doi-asserted-by":"crossref","first-page":"e14743","DOI":"10.1111\/ctr.14743","article-title":"The use of non-transplant biologics in solid organ transplant recipients: A practical review for the frontline clinician","volume":"36","author":"Szczepanik","year":"2022","journal-title":"Clin. Transplant."},{"key":"10.1016\/j.humimm.2024.110810_b0180","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/MOT.0000000000000615","article-title":"The parallel paradigm between intestinal transplant inflammation and inflammatory bowel disease","volume":"24","author":"Belyayev","year":"2019","journal-title":"Curr. Opin. Organ Transplant."},{"key":"10.1016\/j.humimm.2024.110810_b0185","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/TP.0000000000004285","article-title":"Anti-interleukin-6 antibody clazakizumab in antibody-mediated renal allograft rejection: accumulation of antibody-neutralized interleukin-6 without signs of proinflammatory rebound phenomena","volume":"107","author":"Borski","year":"2023","journal-title":"Transplantation"},{"key":"10.1016\/j.humimm.2024.110810_b0190","doi-asserted-by":"crossref","first-page":"e14936","DOI":"10.1111\/ctr.14936","article-title":"Tocilizumab for treatment of chronic active antibody-mediated rejection in kidney transplant recipients","volume":"37","author":"Boonpheng","year":"2023","journal-title":"Clin. Transplant."},{"key":"10.1016\/j.humimm.2024.110810_b0195","doi-asserted-by":"crossref","first-page":"e12847","DOI":"10.1111\/petr.12847","article-title":"Impacts of donor-specific anti-HLA antibodies and antibody-mediated rejection on outcomes after intestinal transplantation in children","volume":"21","author":"Petit","year":"2017","journal-title":"Pediatr. Transplant."},{"key":"10.1016\/j.humimm.2024.110810_b0200","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.transproceed.2011.06.050","article-title":"Regulatory T cells in transplantation","volume":"43","author":"Wood","year":"2011","journal-title":"Transpl. Proc."}],"container-title":["Human Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885924000703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885924000703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T20:34:54Z","timestamp":1721939694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0198885924000703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0198885924000703"],"URL":"https:\/\/doi.org\/10.1016\/j.humimm.2024.110810","relation":{},"ISSN":["0198-8859"],"issn-type":[{"value":"0198-8859","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologicals in the prevention and treatment of intestinal graft rejection: The state of the art Biologicals in Intestinal Transplantation","name":"articletitle","label":"Article Title"},{"value":"Human Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humimm.2024.110810","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of American Society for Histocompatibility and Immunogenetics.","name":"copyright","label":"Copyright"}],"article-number":"110810"}}